Literature DB >> 8547072

Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia.

H Myint1, J A Copplestone, J Orchard, V Craig, D Curtis, A G Prentice, M D Hamon, D G Oscier, T J Hamblin.   

Abstract

We have treated 52 patients with chronic lymphocytic leukaemia (CLL) with fludarabine; 12 developed severe autoimmune haemolysis. Only three had a previous history of haemolytic anaemia. Six out of eight patients retreated with fludarabine after control of their haemolysis developed an exacerbation of the haemolytic anaemia. The cause of autoimmune phenomena in CLL is not known, but our findings reinforce the view that they are caused by a disturbance in immunoregulatory T cells. Fludarabine is a known suppressor of T-cell function.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8547072     DOI: 10.1111/j.1365-2141.1995.tb05300.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  20 in total

Review 1.  New directions in the diagnosis and treatment of chronic lymphocytic leukaemia.

Authors:  Folke Schriever; Dieter Huhn
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  New aspects of the treatment of chronic lymphocytic leukemia.

Authors:  Stefan Faderl; William Wierda; Michael J Keating
Journal:  Curr Hematol Malig Rep       Date:  2006-12       Impact factor: 3.952

Review 3.  Autoimmune complications in chronic lymphocytic leukaemia (CLL).

Authors:  Clive S Zent; Neil E Kay
Journal:  Best Pract Res Clin Haematol       Date:  2010-03       Impact factor: 3.020

Review 4.  Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

Authors:  J C Adkins; D H Peters; A Markham
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 5.  Management of chronic lymphocytic leukaemia.

Authors:  N Kalil; B D Cheson
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

Review 6.  Achieving optimal outcomes in chronic lymphocytic leukaemia.

Authors:  T J Hamblin
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone.

Authors:  Deborah A Bowen; Timothy G Call; Tait D Shanafelt; Neil E Kay; Susan M Schwager; Megan S Reinalda; Kari G Rabe; Susan L Slager; Clive S Zent
Journal:  Leuk Lymphoma       Date:  2010-04

8.  Phase I/II evaluation of pentostatin (2'-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia.

Authors:  S A Johnson; D Catovsky; J A Child; A C Newland; D W Milligan; R Janmohamed
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

9.  Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis.

Authors:  Clive S Zent; Wei Ding; Megan S Reinalda; Susan M Schwager; James D Hoyer; Deborah A Bowen; Diane F Jelinek; Renee C Tschumper; Timothy G Call; Tait D Shanafelt; Neil E Kay; Susan L Slager
Journal:  Leuk Lymphoma       Date:  2009-08

10.  Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.

Authors:  K A Rogers; A S Ruppert; A Bingman; L A Andritsos; F T Awan; K A Blum; J M Flynn; S M Jaglowski; G Lozanski; K J Maddocks; J C Byrd; J A Woyach; J A Jones
Journal:  Leukemia       Date:  2015-10-07       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.